Irritable bowel syndrome (IBS) is a common digestive disorder with unclear causes, affecting about 10% of the global population. Researchers have now discovered that opioid delta-receptor agonists may ...

"I was worried about getting sued, you know, because I was like, God, they're going to sue me if I don't do this fight." ...

The explosive new Boyzone documenary was finally released on Sunday, featuring never-before-seen footage from the band's ...

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

The three-year pilot funded by KKH is also supported by Temasek Foundation, which contributed about $1.8 million. Read more at straitstimes.com.

The 14-year-old boy had been suffering from heart palpitations and stomach aches for a few months since mid-2023. Despite multiple visits to general practitioners and to KK Women’s and Children’s ...

It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

Whether it’s motion sickness, pregnancy, or adverse drug reactions from GLP1 agonists or other drugs, digestive pain ...